# Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

> **NCT01264432** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Peritoneal Carcinomatosis
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01264432
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2016-11-15
- **Final completion:** 2016-11-15
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264432, "Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01264432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*